The company announced 94% efficiency against symptomatic infection
Johnson & Johnson, known as the single-dose vaccine, tends to become a double-dose vaccine, as the US pharmaceutical company announced on Tuesday that a second, booster dose just two months after the first boosts coronavirus antibodies significantly.
Johnson & Johnson said the third and final phase of clinical trials showed 94% efficacy against symptomatic Covid-19 in the US, and 75% protection worldwide.
Significantly, the second dose after two months increased the number of antibodies to four to six times, while the administration after six months offered a control of up to 12-fold increase in antibodies.
Especially against the serious illness, the second dose offered at least 14 days after its administration absolute protection (100%), always according to Johnson & Johnson itself.
In addition, the studies showed good acceptance of the second dose of the vaccine by the organizations of the volunteers who participated in the studies.
The single dose offered 79% protection against infection based on the actual data in the US population, not clinical trials.
The company also stressed that no decline in the effect of the vaccine was recorded during clinical trials from March to July, despite the prevalence of the Delta mutation in the meantime.
source: KAPHIMERINI KYPROU